National Heart, Lung, and Blood Institute's The Framingham Heart Study, Framingham, Massachusetts, USA.
Nat Genet. 2010 Jul;42(7):608-13. doi: 10.1038/ng.604. Epub 2010 Jun 6.
Platelet function mediates both beneficial and harmful effects on human health, but few genes are known to contribute to variability in this process. We tested association of 2.5 million SNPs with platelet aggregation responses to three agonists (ADP, epinephrine and collagen) in two cohorts of European ancestry (N<or=2,753 in the Framingham Heart Study, N<or=1,238 in the Genetic Study of Atherosclerosis Risk). We identified associations of seven loci with platelet aggregation near or within GP6 (P=4.6x10(-13)), PEAR1 (P=3.4x10(-12)), ADRA2A (P=3.3x10(-11)), PIK3CG (P=3.1x10(-9)), JMJD1C (P=1.6x10(-8)), MRVI1 (P=2.0x10(-8)) and SHH (P=4.5x10(-8)). Six of these loci replicated at P<0.05 in an additional African-American cohort (N<or=840 in the Genetic Study of Atherosclerosis Risk). These results provide insights into platelet aggregation pathways and may suggest new antiplatelet therapeutic targets.
血小板功能对人类健康具有双重影响,但目前已知很少有基因可以导致这一过程中的个体差异。我们在两个欧洲血统的队列(弗雷明汉心脏研究中 N<or=2753,动脉粥样硬化风险的遗传研究中 N<or=1238)中测试了 250 万个单核苷酸多态性与三种激动剂(ADP、肾上腺素和胶原)诱导的血小板聚集反应之间的关联。我们在 GP6(P=4.6x10(-13))、PEAR1(P=3.4x10(-12))、ADRA2A(P=3.3x10(-11))、PIK3CG(P=3.1x10(-9))、JMJD1C(P=1.6x10(-8))、MRVI1(P=2.0x10(-8))和 SHH(P=4.5x10(-8))附近或之内的血小板聚集与七个位点之间发现了关联。其中六个位点在动脉粥样硬化风险的遗传研究中的另外一个非裔美国人队列(N<or=840)中达到了 P<0.05 的复制水平。这些结果为血小板聚集途径提供了新的见解,并可能为新的抗血小板治疗靶点提供了线索。